Abstract
Background Zanubrutinib is a Bruton's tyrosine kinase inhibitor that has been recently licensed in refractory mantle cell lymphoma and under assessmen......
小提示：本篇文献需要登录阅读全文，点击跳转登录
Full Text Link
